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Abstract
Several molecular markers drive diagnostic classification, prog-
nostic stratification, and/or prediction of response to therapy in pa-
tients with gliomas. Among them, IDH gene mutations are valuable
markers for defining subtypes and are strongly associated with epi-
genetic silencing of the methylguanine DNA methyltransferase
(MGMT) gene. However, little is known about the percentage of
MGMT-methylated alleles in IDH-mutated cells or the potential as-
sociation between MGMT methylation and deletion of chromosome
10q, which encompasses the MGMT locus. Here, we quantitatively
assessed MGMT methylation and IDH1 mutation in 208 primary gli-
oma samples to explore possible differences associated with the IDH
genotype. We also explored a potential association between MGMT
methylation and loss of chromosome 10q. We observed that MGMT
methylation was heterogeneously distributed within glioma samples
irrespective of IDH status suggesting an incomplete overlap between
IDH1-mutated and MGMT-methylated alleles and indicating a par-
tial association between these 2 events. Moreover, loss of one
MGMT allele did not affect the methylation level of the remaining
allele. MGMT was methylated in about half of gliomas harboring a
10q deletion; in those cases, loss of heterozygosity might be consid-
ered a second hit leading to complete inactivation of MGMT and fur-
ther contributing to tumor progression.
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INTRODUCTION
Gliomas are the most common primary brain tumors in
adults, accounting for approximately 70% of all CNS neo-
plasms (1). They are classified on the basis of clinicopatholog-
ical and histological assessment as either low-grade gliomas
(LGGs), including World Health Organization (WHO) grade I
and grade II tumors, or high-grade gliomas (HGGs), desig-
nated grade III and grade IV tumors (2, 3).
The optimal treatment regimen of patients with LGGs is
currently disputed but the therapeutic approach for primary
HGGs includes maximal safe resection of the tumor followed
by a 6-week course of radiotherapy, with concomitant sys-
temic therapy using the alkylating agent temozolomide (TMZ)
(4–6). Use of this combination therapy (known as the Stupp
protocol) has increased the survival of patients with HGGs,
although median survival remains only approximately 15
months (7).
The conventional classification of glioma subtypes can
be enhanced by their molecular characterization, which is
aimed at identifying clinically important biomarkers. A num-
ber of genetic and epigenetic features useful for diagnostic
classification, prognostic stratification, and/or prediction of re-
sponse to therapy have indeed been identified (8–12). Among
them, mutations in the IDH1 and IDH2 genes, which encode
isocitrate dehydrogenases, are considered valuable diagnostic
and prognostic markers. IDH1 is mutated in 50%–80% of as-
trocytomas, oligodendrogliomas, oligoastrocytomas, and sec-
ondary glioblastomas, with R132H the most common muta-
tion (90%). IDH2 is mutated in approximately 3% of gliomas
(13). It is likely that mutations in the IDHs represent an early
event in tumor development, and it has been suggested that
they may occur in the neoplastic cell of origin (14). Indeed,
IDH1 mutations are strongly associated with other driver alter-
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ations, namely, TP53 mutations and the 1p/19q co-deletion, in
diffuse gliomas (15).
Mutations of the IDH genes confer an enzymatic gain-of-
function phenotype, associated with production of the alterna-
tive metabolite, 2-hydroxyglutarate (16). Accumulation of 2-
hydroxyglutarate impairs DNA demethylation, leading to meth-
ylome and transcriptome remodeling (17, 18), thereby trigger-
ing the glioma-CpG island methylator phenotype (G-CIMP)
(19, 20). Among methylated genes, the O6-methylguanine
DNA methyltransferase (MGMT) promoter frequently under-
goes methylation in the presence of IDH mutations, suggesting
a possible molecular link between the two events (21, 22).
MGMT acts as a tumor suppressor gene that functions in
DNA repair (23) and plays a fundamental role in maintaining
genome integrity by removing O6-alkylguanine DNA adducts
induced by radiotherapy or alkylating agents (i.e. TMZ or
nitrosourea derivatives), which are used as adjuvant therapy
in patients with HGGs. Because the best understood mecha-
nism of MGMT inactivation is its epigenetic silencing via pro-
moter methylation, MGMT methylation status predicts the re-
sponse to alkylating therapy and is, therefore, an indicator of
patient survival (24). Overall, 80% of LGGs and 35%–45% of
HGGs show MGMT methylation (25).
Although MGMT methylation has been extensively
studied in a number of tumors, many key points remain
unclear. Indeed, while the association between MGMT meth-
ylation and IDH mutations is well established (26), little is
known about the timing of MGMT silencing during glioma-
genesis, the percentage of MGMT-methylated alleles in IDH-
mutated cells, or the possible association of MGMT loss with
MGMT methylation.
MGMTmaps to chromosome 10q26.3. Loss of heterozy-
gosity (LOH) of 10q is frequent in gliomas and is classically
associated with HGGs, where it is a negative prognostic
marker (27). In theory, 10q LOH spanning the MGMT locus
should lead to its haploinsufficiency and, therefore, have an
analogous effect on gene expression to that of the methylation
of one allele.
To date, IDH mutation analysis has been performed by
direct sequencing or immunohistochemistry, which allow the
detection but not the quantification of mutations; comparable
results are found using both techniques (28). MGMT methyla-
tion is routinely assessed by methylation-specific PCR, despite
the proclivity of this technique to generate false-positive/
negative results and the fact that it is not quantitative (29).
In this study, we used a quantitative approach to evalu-
ate IDH1 mutations and MGMT promoter methylation in 208
primitive gliomas. We also analyzed MGMT deletion in the
same cases to explore the distribution of these biomarkers and
possible associations between them, considering potential ad-
ditive effects and their clinical significance.
MATERIALS ANDMETHODS
Patients and Samples
This study included 208 primitive gliomas collected
consecutively between 2011 and 2014. The series included 29
LGGs (12 diffuse astrocytomas, 13 oligodendrogliomas, and 4
oligoastrocytomas) and 179 HGGs (37 grade III, including 24
anaplastic astrocytomas, 12 anaplastic oligoastrocytomas, and
1 anaplastic ganglioglioma, and 142 grade IV glioblastomas)
(Supplementary Data Table S1). Eighty-one patients were fe-
male and 127 were male. The median age at surgery for pa-
tients with grade II, grade III, and grade IV tumors was 48.7
years (range: 19.0–77.0 years), 51.7 years (range: 18.0–78.0
years), and 59.1 years (range: 23.0–91.0 years), respectively.
All surgical treatments were performed at Fondazione IRCCS
Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Karnofski Performance Status was assessed on the day
before surgery. The patients underwent surgical gross total
resection of the lesion. All HGG patients received 6 weeks of
radiotherapy, with concomitant systemic TMZ. Standard treat-
ment involved the administration of a total of 60 Gy in 30–35
fractions of 1.8–2.0 Gy, 5 days per week. Concomitant TMZ
was administered at a dose of 75 mg/m2/day on days 1–42, 1–
1.5 hours before radiotherapy, followed by subsequent TMZ
adjuvant therapy of 150–200 mg/m2/day on days 1–5 every 28
days for 12 cycles (6).
After surgery, histological diagnosis was performed
using hematoxylin and eosin-stained, formalin-fixed paraffin-
embedded (FFPE) tissue samples. Gliomas were staged ac-
cording to the WHO classification (3). Following histological
diagnosis, all patients with HGGs (grades III and IV) under-
went concomitant chemo-radiation therapy according to the
Stupp protocol (7). Overall survival (OS) analysis was per-
formed in the patients with available follow-up (172 patients).
At the end of the study, 16% of patients were alive.
The median OS times for patients with grade II, grade
III, and grade IV gliomas were 29 months (range: 11–53
months), 26 months (range: 5–62 months), and 18 months
(range: 1–90 months), respectively.
Tumor DNA was retrieved from FFPE sections consist-
ing of at least 80% cancer cells, estimated by histological eval-
uation, using the Biostic FFPE tissue DNA isolation Kit (MO
BIO Laboratories, Carlsbad, CA), following the manufac-
turer’s instructions.
For MGMT methylation analysis, we also analyzed FFPE
sections from 16 non-tumor brain samples (controls), obtained
from autopsies of age-matched individuals (range: 18–90 years),
who died of causes other than brain malignancies. DNA was
also isolated from peripheral blood lymphocytes (PBLs) using
the QiAMP DNA Mini Kit, according to the manufacturer’s
instructions.
Genotyping of IDH Genes
IDH1 (codon 132) and IDH2 (codon 172) in 172 of 208
gliomas were screened by pyrosequencing. For the remaining
cases, there was insufficient DNA to perform the analysis.
PCR and pyrosequencing were carried out with modifi-
cations as described by Cykowski et al. (30). The primers used
for PCR and pyrosequencing and the amplification, and se-
quencing conditions are shown in Supplementary Data Table
S2A. Results were analyzed using PyroMark ID 1.0 software
(Biotage AB, Uppsala, Sweden). The pyrosequencing ap-
proach allows accurate detection of the proportion of mutated
alleles in the sample (31). Considering that mutations of IDH
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genes are usually heterozygous, a value of 50% for the mu-
tated allele indicates that the alteration is present in virtually
100% of cells.
Evaluation ofMGMTMethylation
MGMT methylation was evaluated in all glioma samples
and normal brain tissue controls. DNA was modified with so-
dium bisulfite, using the EZ DNA Methylation-Gold Kit
(Zymo Research Corp., Irvine, CA). PCR was performed on
20–100 ng of bisulfite-treated DNA, using 10 pmol each of
forward and reverse primers. We analyzed a region covering
10 CpG sites located in the promoter region (Supplementary
Data Table S2B). We focused on these CpGs because it was
previously reported that the methylation of this region shows a
reliable correlation with MGMT gene expression and includes
CpG sites also considered in survival analyses of large clinical
trials (32, 33). Quantitative DNA methylation analysis was
carried out on the Pyro Mark ID instrument using Pyro Gold
Reagents (Qiagen) and 1 pmol of sequencing primer. PCR and
pyrosequencing primers, and amplification and sequencing
conditions are detailed in Supplementary Data Table S2B.
Methylation data were analyzed with Q-CpG software v1.09
(Qiagen) (34, 35). The percentage of methylation was defined
as the mean of the methylation percentages at each CpG site
of the investigated region.
Chromosome 10q LOH
We investigated chromosome 10q deletions in 84 of 208
glioma samples, depending on DNA availability. We used 2
different approaches as follows: when PBLs were available
(76 cases), we compared the genotypes of short tandem
repeats (STRs) in PBLs and tumor DNAs, whereas in the ab-
sence of normal tissue for comparison, array-comparative ge-
nomic hybridization (CGH) was performed (8 cases).
For STR analysis, 100 ng of DNA from both tumor and
PBL samples was PCR amplified and analyzed by capillary
gel electrophoresis on the GeneMapper ABI 3130XL system
(Applied Biosystems, Foster City, CA). Seven STRs span-
ning 11 Mb (D10S1483, D10S587, D10S1727, D10S1676,
D10S169, D10S1770, and D10S212) were used to investigate
the region neighboring MGMT (10q26.3). The genomic loca-
tions and primer sequences of STRs are provided in Supple-
mentary Data Table S2C. MGMT LOH was defined as LOH
of at least 2 informative STRs encompassing the MGMT locus
and was calculated according to the peak-height ratio, as pre-
viously reported (36).
Array-CGH analysis was performed using the Agilent
Technologies Platform (Santa Clara, CA) and samples were
screened with the Sure Print G3 Human CGH Microarray con-
taining 60,000 oligonucleotide probes. Labeling, purification,
and hybridization of DNA samples were carried out according
to the manufacturer’s protocols (Agilent Oligonucleotide
Array-Based CGH for Genomic DNA Analysis, version 7.3).
Slides were evaluated by the DNA Microarray Scanner (Agi-
lent Technologies) and TIFF images were obtained using Agi-
lent Scan Control software. Raw data were generated using
Agilent Feature extraction and analyzed by Agilent Cytoge-
nomics 2.7. Copy number variation analysis was performed
using the ADAM2 algorithm. To improve the accuracy of the
results, the Diploid Peak Centralization algorithm was applied.
The aberration filter was set to detect a minimum of 3 consec-
utive probes/region and the minimum absolute average log ra-
tio (MAALR) was60.25. A second analysis was performed
using a MAALR of60.15 with a minimum number of 5
probes/region to detect low level of mosaicism.
Statistical Analyses
The Fisher exact, Chi-square, and Mann-Whitney tests
were used to identify possible correlations between molecular
markers and clinical variables. Kaplan-Meier survival curves
and the Log-rank test allowed us to investigate survival differ-
ences among groups. Correlations between MGMT methyl-
ation levels and OS were identified by Cox regression and
Kruskal-Wallis tests.
RESULTS
The Significance of Molecular Markers in
Glioma Grading
IDH1 R132H was the only mutation present in the sam-
ples. It was found in 30 of 172 tumors (17%) and 84%, 26%,
and 5.5% of grade II, grade III, and grade IV, respectively,
confirming an inverse correlation with tumor grade (p<
0.00001, Chi-square test) (Fig. 1A) (13).
For MGMT methylation analysis, we first defined the
normal methylation range in 16 control brain samples as 0%–
4% (Supplementary Data Table S3). Taking into account the
analytical sensitivity of pyrosequencing (5%), we considered
cases with MGMT methylation levels9% to be methylated.
Moreover, MGMT methylation at all the analyzed CpG sites
was stable, in both controls and glioma samples (Supplemen-
tary Data Tables S3 and S4). Overall, MGMT methylation was
present in 121/208 samples (58%). LGGs were more fre-
quently methylated (83% of cases) compared with HGGs
(65% of grade III and 53% of grade IV cases) (p¼ 0.008, Chi-
square test) (Fig. 1A). In addition, considering all cases,
MGMT methylation percentages inversely correlated with tu-
mor grade (p¼ 0.04, Kruskal-Wallis test). The median meth-
ylation levels (interquartile range) in grade II, grade III, and
grade IV gliomas were 29% (9%–44%), 24% (3%–61%), and
9% (3%–47%), respectively (Fig. 1B).
Chromosome 10q LOH spanning the MGMT locus was
observed in 9%, 56%, and 75% of grade II, grade III, and grade
IV gliomas, respectively, confirming a positive correlation
with tumor grade (p¼ 0.0002, Chi-square test) (36) (Fig. 1A).
In grade II and grade III gliomas, the IDH1 mutation was
predominantly observed in MGMT-methylated tumors: 16 of
19 (84%) grade II tumors (p¼ 0.0012, Fisher exact test) and 7
of 27 (26%) grade III tumors (p¼ 0.0216, Fisher exact test).
Conversely, grade IV tumors lacked this association. Specifi-
cally, of the 126 grade IV gliomas, 4 were positive for IDH1
mutation and MGMT methylation, 3 were IDH1-mutated and
MGMT-unmethylated, 55 were IDH wild-type and MGMT
unmethylated, and 66 were IDH wild-type and MGMT
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methylated (Fig. 1C). This suggests that in grade IV gliomas,
MGMT methylation occurs independently of IDH1 genotype.
When examining the possible association between 10q LOH
and MGMT methylation, we noticed that among the 10q de-
leted cases, 28 (54%) were MGMT methylated, suggesting that,
in these cases, MGMT was completely inactivated by the 2
events. In addition, the majority of 10q deleted tumors (92%)
were IDH1 wild-type (Supplementary Data Table S1; Fig. 1C).
Evaluation of the distribution of MGMT methylation
levels in methylated cases (methylation 9%) according to
IDH1 R132H 10q loss
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FIGURE 1. Prevalence of the IDH1 mutation, methylguanine DNA methyltransferase (MGMT) methylation, and 10q loss of
heterozygosity (LOH) and association of these molecular markers in histologically classified gliomas. (A) The IDH1 R132H
mutation and MGMT methylation are inversely correlated with tumor grade, whereas 10q loss correlates positively with tumor
grade. *p values were calculated using the Chi-square test. The number of cases is indicated at the top of each vertical bar. (B)
MGMT methylation values (%) correlate inversely with tumor grade. Vertical bars indicate the interquartile range (IQR). *p value
was calculated using the Kruskal-Wallis test. (C) Significant associations (*) were found between IDH1 mutation and MGMT
methylation in grade II and III gliomas. No associations were observed between 10q LOH and the other analyzed markers.
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IDH1 mutation status did not provide any evidence of differ-
ences in median methylation levels (median range in all
groups, 32–47%) (Table), suggesting that the IDH1 mutation
does not influence MGMT methylation levels. Similarly, no
association was observed between MGMT methylation levels
and 10q LOH (Table).
Distribution ofMGMT-Methylated Alleles in
Gliomas
Quantitative IDH1 genotyping showed that the R132H
mutation was present in 21–53% of alleles (mean: 46%) (Fig.
2A; Table; Supplementary Data Table S1). Considering that
tumor samples contained at least 80% tumor cells, as deter-
mined by histological evaluation, and that IDH mutations are
commonly heterozygous, we can assume that the majority of
tumor cells carried one mutated allele.
TABLE.MedianMGMTMethylation Values in Cases Showing
Methylation levels9%, According to Tumor Grade, IDH1 Sta-
tus and 10q Loss
MGMTmethylation values (%)
Grade II Grade III Grade IV
No. Median
(range)
No. Median
(range)
No. Median
(range)
IDH1 status Mut (R132H) 7 36 (16–70) 16 32 (15–67) 4 32 (22–45)
WT 9 40 (10–74) 0 63 34 (10–87)
10q LOH 0 7 40 (10–70) 21 47 (9–86)
NO LOH 9 31 (22–67) 5 36 (16–52) 7 41 (20–56)
LOH, loss of heterozygosity.
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FIGURE 2. Distribution of IDH1 R132H-mutated and MGMT-methylated alleles in IDH1-mutated and wild-type gliomas. (A)
Distribution of IDH1-mutated alleles in glioma samples. The majority of cases carrying mutations (25 of 30) harbored
approximately 50% (41%–60%) of mutated alleles, indicating that all tumor cells in the analyzed samples carry the heterozygous
mutation. (B) Distribution of MGMT-methylated alleles in IDH1-mutated tumors. Three of 30 (10%) IDH1-mutated tumors were
MGMT unmethylated (mean methylation: 0%–8%). Twenty-seven of 30 mutated tumors showed a heterogeneous distribution of
the methylated alleles, ranging from 15% to 70%, suggesting that not all cells in the tumor carry MGMT-methylated alleles. (C)
Distribution of MGMT-methylated alleles in IDH1 wild-type tumors. Sixty-nine out of 144 (48%) IDH1 wild-type gliomas were
MGMT-unmethylated (mean methylation level 0%–8%); the remaining 75 cases showed variable levels of MGMT methylation
(9%–87%).
J Neuropathol Exp Neurol • Volume 75, Number 8, August 2016 MGMT Methylation, IDH, and 10q Deletion in Gliomas
795
In samples with IDH1 mutations, the percentage of
MGMT methylation ranged from 5% to 70% (mean 32%;
Fig. 2B). In principle, in a homogenous cell population in
which MGMT is either methylated or not, the methylation per-
centage of CpG stretches directly involved in gene expression
should approximate the following values: 0% (both alleles
unmethylated); 50% (1 allele methylated and 1 unmethylated;
i.e. imprinted loci); and 100% (both alleles methylated). Inter-
mediate percentages of methylation (as we found in the major-
ity of the samples) suggest that the tumor contains a mixture
of cells carrying fully methylated alleles and cells with
unmethylated alleles. The nonoverlapping distribution of
IDH1-mutated and MGMT-methylated alleles in a tumor sam-
ple indicates that while the IDH1 mutation is present in virtu-
ally all cancer cells, MGMT is methylated in a variable
subgroup (Figs. 2B and 3A–C). Analogous results can be ex-
trapolated for IDH wild-type cases, in which histological eval-
uation confirmed that samples consisted of at least 80% cancer
cells (Figs. 2C and 3D–F).
Finally, MGMT methylation was present in 28 of 52
cases, with 10q LOH spanning the MGMT locus. These tumors
were mostly (21 of 28) grade IV, suggesting that, in more
FIGURE 3. IDH1 R132H-mutated and MGMT-methylated alleles within glioma samples. Hematoxylin and eosin (H&E) staining
(A, D), IDH1 R132H (B, E), and MGMT methylation (C, F) in 2 representative cases (DA8 and GBM90) (Table; Supplementary
Data Table S1). (A–C) H&E staining of a representative case of diffuse astrocytoma showing approximately 80% of tumor cells
(A). IDH1 pyrograms indicating that 47% of alleles carry the R132H mutation (B) and the percentage of MGMT methylation in
the sample is 15% (C). (D–F) H&E staining of a representative case of glioblastoma, showing approximately 80% of tumor cells
(D). IDH1 pyrograms indicating that the tumor is wild-type (E) and that the percentage of MGMT methylation in the sample is
86% (F).
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advanced tumors, MGMT can be silenced by a two-hit mecha-
nism (i.e. 1 allele deleted and 1 methylated).
MGMTMethylation Affects OS Independently of
IDH1Mutation
Correlations between molecular markers and OS were
evaluated in all patients with available follow-up (172 cases in
total). Because all patients followed the same therapeutic pro-
tocol, we assume that the observed differences in OS between
experimental groups were independent of treatment.
Univariate analysis of molecular markers highlighted
that IDH1 mutation correlated positively with OS in both
LGGs and HGGs (p< 0.0001 and p¼ 0.0116, respectively,
Log-rank test) (Fig. 4A, C). The median OS for patients with
IDH1 mutations was 31 months for LGGs and 34 months for
HGGs. Conversely, the median OS of IDH1 wild-type patients
was 14 months for LGGs and 18 months for HGGs.
MGMT methylation conferred a survival advantage on
both LGGs and HGGs (p< 0.0001, Log-rank test). The me-
dian OS for LGGs patients was 32 months in methylated ver-
sus 14 months in non-methylated cases (Fig. 4B). Similarly,
the median OS for HGGs patients was 24 months in methyl-
ated versus 14 months in nonmethylated cases (Fig. 4D).
Importantly, a significant positive correlation was found be-
tween methylation levels and OS (p< 0.0001 and e¼0.019,
Cox regression) (Fig. 5A, B). The distribution of OS (deter-
mined at 6-month intervals) for unmethylated compared with
methylated cases revealed that 75% of MGMT-unmethylated
patients died within 18 months from surgery, whereas more
than half of MGMT-methylated patients survived for longer
than 18 months. In particular, 24 of 98 (24%) MGMT-methyl-
ated cases can be considered long-term survivors (OS>36
months) (Fig. 5B). We also found that the methylation levels
in glioma samples grouped by OS intervals (every 6 months)
increased with increasing OS (p¼ 0.001, Kruskal-Wallis test)
(Fig. 5C). Moreover, patients with MGMT-methylated HGGs
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FIGURE 4. Prognostic significance of IDH1 mutation and MGMT methylation in low-grade gliomas (LGGs) and high-grade
gliomas (HGGs). (A–D) Kaplan-Meier survival analysis of LGGs (A, B) and HGGs (C, D) according to IDH1 genotype (A, C) and
MGMTmethylation status (B, D). Both molecular markers are associated with improved OS.
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had longer OS, independent of IDH1 mutation status (p¼
0.0337 and p¼ 0.0020 for IDH1 mutated and wild-type, re-
spectively, Log-rank test) (Supplementary Data Fig. S1).
Multivariate analysis suggested that both IDH1 muta-
tion and MGMT methylation significantly affected OS (p¼
0.0162 and p¼ 0.0037, respectively), but MGMT methylation
shows a more positive correlation with OS (e¼0.01476,
hazard ratio¼ 0.9853) compared to IDH1 mutation (e¼
0.8057, hazard ratio¼ 0.4468), emphasizing its role as a
strong marker of positive prognosis.
Finally, in our population, 10q LOH did not influence
OS independently of MGMT methylation status.
DISCUSSION
This study demonstrates that, whatever the underlying
mechanism, MGMT promoter methylation is not homoge-
neously distributed in glioma samples, suggesting that only
a fraction of cells in the tumor bulk is sensitive to MGMT
epigenetic silencing. Overall, our data on grade II and grade
III gliomas indicate that IDH1 mutation and MGMT methyla-
tion are often found concomitantly, as previously reported
(26). However, the non-homogeneously overlapping distribu-
tion of IDH1-mutated and MGMT-methylated alleles is indica-
tive of an incomplete association between these 2 molecular
events. In particular, the distribution of IDH1-mutated alleles
confirmed, as expected for a heterozygous mutation, that the
gene was mutated in virtually all cancer cells and that the
IDH1 mutation is an early event in gliomagenesis. This result
supports the hypothesis that IDH1 mutation triggers G-CIMP
(20) and confers only an increased likelihood of MGMT meth-
ylation in tumor cells (37).
In addition, in grade IV gliomas, IDH mutation and
MGMT methylation seem to be independent events, as indi-
cated by the presence of a consistent subgroup of MGMT-
methylated/IDH1 wild-type tumors. Similar to IDH1-mutated
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gliomas, wild-type tumors showed a heterogeneous distribu-
tion of MGMT-methylated alleles, suggesting that, whatever
the underlying mechanism, MGMT epigenetic silencing oc-
curs in only a subset of tumor cells.
Our data suggest that IDH1 mutation (or other unknown
mechanisms) may predispose to MGMT methylation in a
variable percentage of tumor cells. Whether methylated cells
are randomly distributed or occur in a precise niche within
the tumor is unknown. It is conceivable that, given the crucial
role of MGMT in the maintenance of genome integrity, its
epigenetic silencing may lead to mutation acquisition and
thus contribute to promotion or maintenance of neoplastic
transformation.
We confirmed that MGMT methylation is inversely cor-
related with tumor grade (13); however, no differences were
found in MGMT methylation levels of glioma samples
grouped according to 10q LOH, implying that the lack of one
MGMT allele does not affect the methylation of the remaining
allele. We also observed that in approximately 50% of HGGs
with LOH at the MGMT locus, the second allele was methyl-
ated, suggesting that in advanced stages of gliomagenesis,
MGMT could be completely inactivated by methylation of one
allele and deletion of the other.
Our data also confirm MGMT methylation as a positive
prognostic factor in both IDH1-mutated and wild-type gliomas
(25), with the percentage of MGMT methylation showing a di-
rect correlation with increasing OS (38). Increased OS in pa-
tients with MGMT methylation is attributable to a positive re-
sponse to TMZ, rather than a biological effect on tumor
development. Because we did not observe any improvement
in the OS of patients with both MGMT methylation and 10q
LOH, we hypothesize that the positive effect of complete
MGMT silencing on therapy response can be counterbalanced
by the loss of other tumor suppressor genes (e.g. PTEN,
ERCC6 and DMBT1) mapping to the same region of chromo-
some 10q and associated with reduced OS (39, 40).
These findings confirm the importance of quantitative
evaluation of MGMT methylation in the clinical assessment of
patients with glioma, taking into account the proportion of tu-
mor cells in the samples, to facilitate accurate evaluation of
the percentage of MGMT methylation in the tumor. To enable
a better understanding of the role of MGMT methylation phe-
nomenon in gliomagenesis, the mechanism underlying MGMT
methylation should be examined in detail along with the iden-
tification of tumor cells that are more susceptible to the acqui-
sition of DNA methylation.
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